Retatrutide vs Tirzepatide: Key Differences

Retatrutide and tirzepatide are two of the most studied peptides in metabolic research, and they are often discussed side by side. They are related — both are incretin-based multi-agonists — but they are not the same, and the difference between them genuinely matters to researchers.

The headline difference: two targets vs three

Tirzepatide is a dual agonist, acting on the GLP-1 and GIP receptors. Retatrutide is a triple agonist, engaging GLP-1, GIP and, crucially, the glucagon receptor as well. That third target — the glucagon receptor — is the single biggest distinction between the two compounds and the reason they behave differently in research models.

Why the glucagon receptor matters

Adding glucagon-receptor activity changes the picture. The glucagon receptor is associated with energy expenditure, so a molecule that engages it alongside the two incretin receptors gives researchers a way to study a broader slice of metabolic regulation in a single experiment. This is the central reason retatrutide is so often framed as a “next step” beyond dual agonists.

Why study both?

Comparing a dual agonist and a triple agonist directly helps researchers isolate the contribution of each receptor pathway. By holding two targets constant and adding a third, the literature can begin to tease apart which effects come from which receptor — exactly the kind of question comparative research is built to answer.

At a glance

Tirzepatide: GLP-1 + GIP — a dual agonist and a well-established research benchmark. Retatrutide: GLP-1 + GIP + glucagon — a triple agonist representing the newer, multi-target direction of metabolic research. Both are supplied by Auriva as lyophilised vials and pre-filled pens.

Important

Both compounds are supplied strictly for laboratory and research purposes only. They are not for human consumption and are not medicines.

Compare them in the Auriva range: retatrutide and tirzepatide.